Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | PTGES | O14684 | 2/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.31 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16559047 | 0.94 | TAAR1 (0.33) | TAAR1NPC1RAB9ACNR1ALOX5 | |
| SCHEMBL880647 | 0.91 | PTGES (0.32) | TAAR1NPC1RAB9ACNR1PTGES | |
| SCHEMBL16172321 | 0.90 | NOS1 (0.36) | CNR1ALOX5EPHX2PTGESPLAU | |
| SCHEMBL16169716 | 0.84 | FFAR1 (0.33) | CNR1ALOX5EPHX2PTGESPLAU | |
| SCHEMBL15244959 | 0.84 | TACR1 (0.34) | FFAR1 | |
| SCHEMBL10198719 | 0.82 | TAAR1 (0.38) | TAAR1CNR1PTGESFFAR1 | |
| SCHEMBL15245061 | 0.81 | ACACB (0.33) | — | |
| SCHEMBL15805985 | 0.80 | ACACB (0.38) | PLAUST14FFAR1ASIC3 | |
| SCHEMBL16603510 | 0.78 | GRIN2B (0.33) | F10 | |
| SCHEMBL85784 | 0.77 | TAAR1 (0.53) | TAAR1PLAUFFAR1ASIC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10603294-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190282521-A1 | Compounds For Use In Treatment Of Mucositis | POLYMEDIX, INC. | 2019-09-19 | — | — | US | disclosed |
| US-10206894-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180064664-A1 | Compounds For Use In Treatment of Mucositis | POLYMEDIX, INC. | 2018-03-08 | — | — | US | disclosed |
| US-20180064664-A1 | Compounds For Use In Treatment of Mucositis | POLYMEDIX, INC. | 2018-03-08 | — | — | US | disclosed |
| US-9795575-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9795575-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-2709619-B1 | COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS | CELLCEUTIX CORP (US) | 2017-10-11 | — | — | EP | disclosed |
| US-20170224640-A1 | Compounds For Use In Treatment Of Mucositis | INNOVATION PHARMACEUTICALS INC. | 2017-08-10 | — | — | US | disclosed |
| US-20170224640-A1 | Compounds For Use In Treatment Of Mucositis | INNOVATION PHARMACEUTICALS INC. | 2017-08-10 | — | — | US | disclosed |
| US-8222456-B2 | Facially amphiphilic polyaryl and polyarylalkynyl polymers and oligomers and uses thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222456-B2 | Facially amphiphilic polyaryl and polyarylalkynyl polymers and oligomers and uses thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-07-17 | — | — | US | disclosed |
| EP-2433628-A1 | Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer | The Trustees Of The University Of Pennsylvania (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20120039945-A1 | Methods Of Immune Modulation | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120039945-A1 | Methods Of Immune Modulation | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-02-16 | — | — | US | disclosed |
| EP-2301349-A2 | Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer | The Trustees of The University of Pennsylvania (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2298074-A2 | Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer | The Trustees Of The University Of Pennsylvania (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20100081665-A1 | Anti-Malarial Compounds | CELLCEUTIX CORPORATION | 2010-04-01 | — | — | US | disclosed |
| US-20090092574-A1 | Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof | MIDCAP FINANCIAL SBIC, LP, AS ADMINISTRATIVE AGENT | 2009-04-09 | — | — | US | disclosed |
| US-20090092574-A1 | Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof | MIDCAP FINANCIAL SBIC, LP, AS ADMINISTRATIVE AGENT | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170224640-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | TAAR1 4726/4885NPC1 571/4885RAB9A 2835/4885 |
| US-10603294-B2 | Compounds for use in treatment of mucositis | MUC1, FUT6, MMP8 | TAAR1 4726/4885NPC1 571/4885RAB9A 2835/4885 |
| US-20120039945-A1 | Methods Of Immune Modulation | IFNG, CD14, TLR3 | TAAR1 2693/4885NPC1 1461/4885RAB9A 3042/4885 |
| US-10206894-B2 | Compounds for use in treatment of mucositis | MUC1, FUT6, SI | TAAR1 4831/4885NPC1 791/4885RAB9A 3674/4885 |
| US-20090092574-A1 | Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof | OTC, OCIAD2, OCIAD1 | TAAR1 3953/4885NPC1 198/4885RAB9A 3404/4885 |
| US-20100081665-A1 | Anti-Malarial Compounds | AADAC, ME2, HTRA2 | TAAR1 3166/4885NPC1 121/4885RAB9A 2029/4885 |
| US-20190282521-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | TAAR1 4726/4885NPC1 571/4885RAB9A 2835/4885 |
| US-20180064664-A1 | Compounds For Use In Treatment of Mucositis | MUC1, FUT6, SI | TAAR1 4831/4885NPC1 791/4885RAB9A 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.